Lupin Stock

Lupin Tangible Book Value per Share

The Tangible Book Value per Share of Lupin (LUPIN.NS) as of Aug 24, 2026 is 272.91 INR. In the previous year, Tangible Book Value per Share was 221.76 INR — a change of 23.07% (higher).

Tangible Book Value per Share

272.91INR

YoY

23.07%

Last updated:

Tangible Book Value per Share of Lupin is 2026 272.91 INR. Tangible Book Value per Share of Lupin was 2025 221.76 INR. It decreases by 23.07% higher compared to the previous year.

The Lupin Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
141.82 INR
Jan 1, 2019
152.00 INR
Jan 1, 2020
192.19 INR
Jan 1, 2021
220.81 INR
Jan 1, 2022
197.45 INR
Jan 1, 2023
184.06 INR
Jan 1, 2024
221.76 INR
Jan 1, 2025
272.91 INR
The Lupin Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
272.91INR+23.07%
221.76INR+20.48%
184.06INR-6.78%
197.45INR-10.58%
220.81INR+14.89%
192.19INR+26.44%
152.00INR+7.18%
141.82INR+14.04%
124.36INR+39.48%
89.16INR-44.93%
161.91INR+20.11%
134.80INR+32.54%
101.71INR+39.08%
73.13INR+17.98%
61.98INR+32.95%
46.62INR+76.80%
26.37INR-0.70%
26.56INR+23.06%
21.58INR+40.14%
15.40INR
Access this data via the Eulerpool API

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Tangible Book Value per Share of Lupin is 272.91 INR in 2026.

Tangible Book Value per Share of Lupin changed from 221.76 INR to 272.91 INR, representing a 23.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Lupin since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

Balance Sheet — Lupin

All Key Metrics — Lupin